These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 9198227

  • 1. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
    Murphy S.
    Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
    [Abstract] [Full Text] [Related]

  • 2. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [Abstract] [Full Text] [Related]

  • 3. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, van Vliet HH.
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [Abstract] [Full Text] [Related]

  • 4. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T, Finazzi G.
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [Abstract] [Full Text] [Related]

  • 5. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [Abstract] [Full Text] [Related]

  • 6. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

  • 7. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 8. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
    Randi ML, Fabris F, Ruzzon E, Pacquola E, Cella G, Girolami A.
    Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
    [Abstract] [Full Text] [Related]

  • 9. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Cancer J; 2007 Nov; 13(6):372-6. PubMed ID: 18032974
    [Abstract] [Full Text] [Related]

  • 10. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [Abstract] [Full Text] [Related]

  • 11. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
    [Abstract] [Full Text] [Related]

  • 12. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
    Wehmeier A, Südhoff T, Meierkord F.
    Semin Thromb Hemost; 1997 Mar; 23(4):391-402. PubMed ID: 9263357
    [Abstract] [Full Text] [Related]

  • 13. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH.
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [Abstract] [Full Text] [Related]

  • 14. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
    Barbui T, Finazzi G.
    Curr Hematol Rep; 2003 May; 2(3):248-56. PubMed ID: 12901347
    [Abstract] [Full Text] [Related]

  • 15. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
    Elliott MA, Tefferi A.
    Br J Haematol; 2005 Feb; 128(3):275-90. PubMed ID: 15667529
    [Abstract] [Full Text] [Related]

  • 16. Polycythemia vera and essential thrombocythemia in young patients.
    Frezzato M, Ruggeri M, Castaman G, Rodeghiero F.
    Haematologica; 1993 Feb; 78(6 Suppl 2):11-7. PubMed ID: 8039752
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR.
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [Abstract] [Full Text] [Related]

  • 18. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A, Anagrelide Study Group.
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [Abstract] [Full Text] [Related]

  • 19. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
    Wehmeier A, Daum I, Jamin H, Schneider W.
    Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
    [Abstract] [Full Text] [Related]

  • 20. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
    Landolfi R, Di Gennaro L, Novarese L, Patrono C.
    Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.